Hepatocellular Carcinoma Surveillance and Detection Strategies

Hepatocellular carcinoma (HCC) ranks among the leading causes of cancer-related mortality worldwide, reflecting both the global prevalence of chronic liver disease and the challenges of detecting tumours at a curable stage. Surveillance is targeted at individuals with established cirrhosis or other high-risk conditions, typically at six-month intervals, to identify early lesions amenable to curative therapy. Conventional approaches combine biannual abdominal ultrasound with serum alpha-fetoprotein measurement, balancing affordability and accessibility against variable sensitivity for lesions below 2 cm. Cross-sectional imaging by contrast-enhanced CT or MRI offers higher accuracy but at increased cost, radiation exposure or limited availability. Recent efforts seek to refine patient stratification by integrating novel circulating biomarkers, risk-prediction models and quantitative image analysis. Abbreviated MRI protocols and emerging radiomic or deep-learning algorithms applied to routine scans promise to enhance lesion conspicuity while reducing examination time and operator dependence. Complementary strategies under investigation include liquid-biopsy assays for circulating tumour DNA, risk-adaptive surveillance intervals and point-of-care elastography to personalise monitoring. Together, these advances aim to shift the diagnostic paradigm from population-based screening to precision surveillance, thereby improving early detection rates, broadening access in resource-limited settings and ultimately reducing HCC mortality on a global scale.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Hepatocellular Carcinoma Surveillance and Detection Strategies publication trend

The graph below shows the total number of articles in hepatocellular carcinoma surveillance and detection strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Hepatocellular carcinoma (HCC): A primary malignancy of hepatocytes, most often arising in the setting of chronic liver injury or cirrhosis.

Cirrhosis: End-stage liver fibrosis characterised by regenerative nodules, compromised hepatic function and elevated risk of HCC.

Alpha-fetoprotein (AFP): A serum glycoprotein biomarker elevated in a subset of HCC cases, used adjunctively with imaging.

Abbreviated MRI protocol: A streamlined liver MRI examination focusing on key contrast-enhanced sequences to reduce scan time and cost.

Radiomics: The extraction and analysis of high-dimensional quantitative features from medical images to characterise tissue heterogeneity.

References

1. Surveillance Imaging and Alpha Fetoprotein for Early Detection of Hepatocellular Carcinoma in Patients With Cirrhosis: A Meta-analysis. Gastroenterology (2018).